FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
DK0668350T4
(da)
*
|
1994-02-16 |
2009-02-23 |
Us Gov Health & Human Serv |
Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom
|
DE69638058D1
(de)
|
1995-06-15 |
2009-11-26 |
Crucell Holland Bv |
Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
US5877011A
(en)
*
|
1996-11-20 |
1999-03-02 |
Genzyme Corporation |
Chimeric adenoviral vectors
|
US5849561A
(en)
*
|
1997-05-22 |
1998-12-15 |
Cornell Research Foundation, Inc. |
Method for the production of non-group C adenoviral vectors
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
US20040204381A1
(en)
*
|
1997-11-12 |
2004-10-14 |
Moskal Joseph R |
Detection and treatment of glyco-enzyme-related disease
|
US6670188B1
(en)
*
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
WO1999055365A1
(en)
*
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
CN1342206A
(zh)
*
|
1998-08-28 |
2002-03-27 |
杜克大学 |
在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
US6224566B1
(en)
|
1999-05-04 |
2001-05-01 |
Cardiodyne, Inc. |
Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
|
PT1054064E
(pt)
*
|
1999-05-17 |
2005-02-28 |
Crucell Holland Bv |
Veiculos de entrega de genes derivados de adenovirus compreendendo pelo menos um elemento de adenovirus do tipo 35
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
EP1157999A1
(de)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
|
NZ524743A
(en)
*
|
2000-09-20 |
2004-07-30 |
Crucell Holland B |
Gene delivery vectors provided with a tissue tropism for dendritic cells provided by a viral capsid protein
|
US7235233B2
(en)
*
|
2000-09-26 |
2007-06-26 |
Crucell Holland B.V. |
Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
|
CA2439185A1
(en)
*
|
2001-02-23 |
2002-09-06 |
Novartis Ag |
Vector constructs
|
US20040253210A1
(en)
*
|
2001-08-30 |
2004-12-16 |
Marjorie Robert-Guroff |
Adenovirus type7 vectors
|
US7375206B2
(en)
*
|
2002-02-22 |
2008-05-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Brother of the regulator of imprinted sites (BORIS)
|
IL164803A0
(en)
*
|
2002-04-25 |
2005-12-18 |
Crucell Holland Bv |
Means and methods for the production of adenovirusvectors
|
AU2003268145A1
(en)
*
|
2002-08-22 |
2004-03-11 |
Merck And Co., Inc. |
Methods for propagating adenovirus and virus produced thereby
|
US20040166091A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
EP1649028B1
(de)
*
|
2003-07-25 |
2012-08-22 |
Genvec, Inc. |
Adenoviralevektoren-basierte impfstoffe
|
ES2340038T3
(es)
|
2003-11-14 |
2010-05-28 |
Genvec, Inc. |
Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
|
EP1692154A4
(de)
*
|
2003-11-24 |
2009-07-08 |
Canji Inc |
Verminderung der hautvernarbung
|
AU2005214090B2
(en)
*
|
2004-02-23 |
2008-09-11 |
Crucell Holland B.V. |
Virus purification methods
|
CN1972958B
(zh)
|
2004-04-12 |
2013-01-23 |
美国政府卫生与公共服务部 |
应用腺病毒载体诱导免疫应答的方法
|
US20090022759A1
(en)
*
|
2004-07-20 |
2009-01-22 |
Hans Gerhard Burgert |
Adenovirus vector and method to manipulate the adenovirus genome
|
EP1784493A2
(de)
*
|
2004-09-01 |
2007-05-16 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Adenovirale vektoren mit der fähigkeit zum umwandeln von apcs, mögliche verwendung bei immunantworterzeugung
|
WO2006086357A2
(en)
*
|
2005-02-10 |
2006-08-17 |
Merck & Co., Inc. |
Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
|
ATE412737T1
(de)
*
|
2005-04-11 |
2008-11-15 |
Crucell Holland Bv |
Virusreinigung mit ultrafiltration
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
CA2620495A1
(en)
*
|
2005-08-31 |
2007-03-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
BRPI0618441B8
(pt)
*
|
2005-11-10 |
2021-07-27 |
Genvec Inc |
vetor adenoviral
|
CA2675022A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US20090202492A1
(en)
*
|
2008-01-25 |
2009-08-13 |
University Of South Florida |
Adenovirus vaccine utilizing ikk as adjuvant
|
CN102056624A
(zh)
*
|
2008-06-04 |
2011-05-11 |
康奈尔大学 |
用于防治成瘾的疫苗
|
JP5770633B2
(ja)
*
|
2008-11-03 |
2015-08-26 |
クルセル ホランド ベー ヴェー |
アデノウイルスベクターの産生方法
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
CN102791852B
(zh)
|
2009-10-15 |
2014-05-07 |
克鲁塞尔荷兰公司 |
纯化腺病毒颗粒的方法
|
CN102575233B
(zh)
|
2009-10-15 |
2014-07-16 |
克鲁塞尔荷兰公司 |
从高细胞密度培养物纯化腺病毒的方法
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
EA201270607A1
(ru)
|
2009-11-09 |
2012-09-28 |
Генвек, Инк. |
Аденовирус обезьян и способы его использования
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
EP2536829B1
(de)
|
2010-02-15 |
2016-04-06 |
Crucell Holland B.V. |
Verfahren zur Herstellung von adenoviralen Ad26-Vektoren
|
US9682133B2
(en)
|
2010-03-17 |
2017-06-20 |
Cornell University |
Disrupted adenovirus-based vaccine against drugs of abuse
|
EP3284821B1
(de)
|
2010-03-23 |
2022-01-05 |
Precigen, Inc. |
Vektoren zur bedingten expression therapeutischer proteine, wirtszellen mit diesen vektoren und verwendungen davon
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
US8771709B2
(en)
|
2010-09-20 |
2014-07-08 |
Crucell Holland B.V. |
Therapeutic vaccination against active Tuberculosis
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
EP3450568A3
(de)
|
2011-03-04 |
2019-04-24 |
Intrexon Corporation |
Vektoren für bedingte proteinexpression
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
CA2850629A1
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
CN103974970B
(zh)
|
2011-10-05 |
2018-01-02 |
金维克有限公司 |
猴腺病毒(大猩猩)或腺病毒载体及其使用方法
|
CN103987726B
(zh)
|
2011-10-05 |
2017-10-03 |
金维克有限公司 |
猴(大猩猩)腺病毒或腺病毒载体及其使用方法
|
WO2013052859A2
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
US20150157700A1
(en)
|
2012-02-02 |
2015-06-11 |
GanVec, Inc. |
Adenoviral vector-based malaria vaccine
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
NZ628385A
(en)
|
2012-03-12 |
2016-09-30 |
Crucell Holland Bv |
Batches of recombinant adenovirus with altered terminal ends
|
CN105431169B
(zh)
|
2012-03-22 |
2019-04-02 |
扬森疫苗与预防公司 |
抗rsv疫苗
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
WO2013154744A1
(en)
|
2012-04-13 |
2013-10-17 |
Cornell University |
Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
|
EP2855669B1
(de)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modifizierte serotyp-28-adenovirusvektoren
|
EP2855511B1
(de)
|
2012-05-29 |
2019-07-24 |
GenVec, Inc. |
Impfstoff gegen das herpes-simplex virus
|
JP6469081B2
(ja)
|
2013-04-25 |
2019-02-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された可溶性融合前rsvfポリペプチド
|
EP3010931B1
(de)
|
2013-06-17 |
2018-06-13 |
Janssen Vaccines & Prevention B.V. |
Stabilisierte lösliche präfusionierte rsv-f-polypeptide
|
EA036046B1
(ru)
|
2013-09-19 |
2020-09-18 |
Янссен Вэксинс Энд Превеншн Б.В. |
Композиция для стабилизации количества, эффективности, инфекционности и качества аденовирусов
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
CN107073091A
(zh)
|
2014-09-07 |
2017-08-18 |
西莱克塔生物科技公司 |
用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
WO2016071306A1
(en)
|
2014-11-04 |
2016-05-12 |
Crucell Holland B.V. |
Therapeutic hpv16 vaccines
|
EP3236998A1
(de)
|
2014-12-24 |
2017-11-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Rekombinante metapneumovirusproteine und deren verwendung
|
EP3247388A1
(de)
|
2015-01-20 |
2017-11-29 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Rekombinantes menschen-/rinder-parainfluenzavirus 3 (b/hpiv3) mit expression eines chimären rsv/bpiv3-f-proteins und verwendungen davon
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
US20180052173A1
(en)
|
2015-03-18 |
2018-02-22 |
Janssen Vaccines & Prevention B.V. |
Assays for recombinant expression systems
|
US10570417B2
(en)
|
2015-04-14 |
2020-02-25 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
WO2017005848A1
(en)
|
2015-07-07 |
2017-01-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
US10456462B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Preventions B.V. |
Vaccine against RSV
|
BR112018003019A2
(pt)
|
2015-08-20 |
2018-09-25 |
Janssen Vaccines & Prevention Bv |
vacinas terapêuticas contra hpv18
|
JP6487604B2
(ja)
|
2015-10-06 |
2019-03-20 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
生物学的製剤のプラスチック誘起分解を防止する方法
|
WO2017139392A1
(en)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
US10808011B2
(en)
|
2016-03-09 |
2020-10-20 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant HIV-1 envelope proteins and their use
|
PL3439672T3
(pl)
|
2016-04-05 |
2021-06-14 |
Janssen Vaccines & Prevention B.V. |
Stabilizowane rozpuszczalne białko f rsv przed fuzją do zastosowania w profilaktyce zakażenia rsv
|
MX2018012095A
(es)
|
2016-04-05 |
2019-01-10 |
Janssen Vaccines & Prevention Bv |
Vacuna contra vrs.
|
CN109922829A
(zh)
|
2016-05-02 |
2019-06-21 |
扬森疫苗与预防公司 |
治疗性hpv疫苗组合
|
CA3023322A1
(en)
|
2016-05-12 |
2017-11-16 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
MX2018014699A
(es)
|
2016-05-30 |
2019-02-28 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del vrs estabilizadas.
|
KR102307065B1
(ko)
|
2016-06-20 |
2021-09-30 |
얀센 백신스 앤드 프리벤션 비.브이. |
강력하고 균형 잡힌 양방향성 프로모터
|
WO2018011196A1
(en)
|
2016-07-14 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
WO2018064523A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
EP3518968B1
(de)
|
2016-10-03 |
2022-01-05 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Hiv-1-env-fusionspeptid-immunogene und deren verwendung
|
US10960070B2
(en)
|
2016-10-25 |
2021-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
EP3554538A2
(de)
|
2016-12-16 |
2019-10-23 |
Institute for Research in Biomedicine |
Neuartige rekombinante rsv-f-präfusionsproteine und verwendungen davon
|
KR20240015743A
(ko)
|
2017-01-07 |
2024-02-05 |
셀렉타 바이오사이언시즈, 인크. |
합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
|
KR102111244B1
(ko)
|
2017-02-09 |
2020-05-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
이종 유전자의 발현을 위한 강력한 짧은 프로모터
|
US11235056B2
(en)
|
2017-03-24 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of HIV-1 gp120 and their use
|
WO2018176103A1
(en)
|
2017-03-30 |
2018-10-04 |
The University Of Queensland |
"chimeric molecules and uses thereof"
|
AU2018267971A1
(en)
|
2017-05-17 |
2019-11-07 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
MX2020002876A
(es)
|
2017-09-15 |
2020-07-22 |
Janssen Vaccines & Prevention Bv |
Metodo para la induccion segura de inmunidad contra el vsr.
|
US20190142974A1
(en)
|
2017-10-13 |
2019-05-16 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
EP3697440A1
(de)
|
2017-10-16 |
2020-08-26 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Rekombinante hiv-1-hüllproteine und deren verwendung
|
KR20200083510A
(ko)
|
2017-10-31 |
2020-07-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 및 이의 용도
|
MX2020004488A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
KR20200074988A
(ko)
|
2017-10-31 |
2020-06-25 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 벡터 및 이의 용도
|
JP7285833B2
(ja)
|
2017-10-31 |
2023-06-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルス及びその用途
|
ES2926243T3
(es)
|
2018-01-23 |
2022-10-24 |
Janssen Vaccines & Prevention Bv |
Vacunas contra virus de la gripe y usos de las mismas
|
EP3758682A4
(de)
|
2018-02-26 |
2021-12-15 |
Antolrx, Inc. |
Tolerogene liposome und verfahren zur verwendung davon
|
EP3762010A4
(de)
|
2018-03-06 |
2022-04-06 |
Precigen, Inc. |
Hepatitis-b-impfstoffe und verwendungen davon
|
WO2020086483A1
(en)
|
2018-10-22 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant gp120 protein with v1-loop deletion
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
CN113597428A
(zh)
|
2019-04-25 |
2021-11-02 |
扬森疫苗与预防公司 |
重组流感抗原
|
US20200360453A1
(en)
|
2019-04-28 |
2020-11-19 |
Selecta Biosciences, Inc. |
Methods for treatment of subjects with preexisting immunity to viral transfer vectors
|
CN113924113A
(zh)
|
2019-05-15 |
2022-01-11 |
扬森疫苗与预防公司 |
季节性流感疫苗与基于腺病毒的呼吸道合胞病毒疫苗的共同施用
|
CA3140234A1
(en)
|
2019-05-15 |
2020-11-19 |
Janssen Vaccines & Prevention B.V. |
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
|
CN114206396A
(zh)
|
2019-05-28 |
2022-03-18 |
西莱克塔生物科技公司 |
用于减弱抗病毒转移载体免疫应答的方法和组合物
|
MX2022002766A
(es)
|
2019-09-05 |
2022-04-06 |
Janssen Vaccines & Prevention Bv |
Vacunas contra el virus de la gripe y usos de las mismas.
|
JP2022551107A
(ja)
|
2019-10-03 |
2022-12-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベクターおよびその使用
|
MX2022005980A
(es)
|
2019-11-18 |
2022-09-07 |
Janssen Biotech Inc |
Vacunas basadas en calr y jak2 mutantes y sus usos.
|
CA3170322A1
(en)
|
2020-02-11 |
2021-08-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sars-cov-2 vaccine
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
CN116096407A
(zh)
|
2020-04-29 |
2023-05-09 |
美国政府(由卫生和人类服务部的部长所代表) |
重组人偏肺病毒f蛋白及其用途
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
US20230029453A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
WO2022035860A2
(en)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Replication-competent adenovirus type 4-hiv env vaccines and their use
|
WO2022232648A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
CA3228275A1
(en)
|
2021-08-03 |
2023-02-09 |
Genoveffa Franchini |
Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
|
WO2023064367A1
(en)
|
2021-10-12 |
2023-04-20 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
WO2023091696A1
(en)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Adenovirus delivery system for cancer treatment
|
WO2023172624A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023192835A1
(en)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Base-covered hiv-1 envelope ectodomains and their use
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
EP4338727A1
(de)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus-formulierungen
|